Inactive Instrument

BioMerieux SA Share Price Xetra

Equities

EYW

FR0010096479

Medical Equipment, Supplies & Distribution

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 3.9B 4.25B 332B Sales 2025 * 4.19B 4.56B 357B Capitalization 11.48B 12.5B 977B
Net income 2024 * 468M 509M 39.84B Net income 2025 * 529M 576M 45.03B EV / Sales 2024 * 2.88 x
Net cash position 2024 * 264M 288M 22.49B Net cash position 2025 * 447M 486M 38.03B EV / Sales 2025 * 2.63 x
P/E ratio 2024 *
25.1 x
P/E ratio 2025 *
22.2 x
Employees -
Yield 2024 *
0.89%
Yield 2025 *
1.03%
Free-Float 36.23%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 52 31/10/16
Chairman 50 15/04/04
Director of Finance/CFO 47 28/02/18
Members of the board TitleAgeSince
Director/Board Member 74 14/09/06
Director/Board Member 63 31/12/04
Chairman 50 15/04/04
More insiders
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW